Type 1 Diabetes - Current and Future Players

Type 1 Diabetes - Current and Future Players

  • Products Id :- GDHC1061FPR
  • |
  • Pages: 63
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Type 1 Diabetes - Current and Future Players


GlobalData has released its pharma report, ''Type 1 Diabetes - Current and Future Players''. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Insomnia Market. The report identifies and analyses the key companies shaping and driving the global Insomnia market. The report provides insight into the competitive Insomnia landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData's team of industry experts.

*This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the purchase.


Investigation of current and future market competition for Type 1 Diabetes

Competitor assessment

Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.

Strategic assessment of Type 1 Diabetes sector through market impact analysis, future market scenario and company analysis

Reasons to buy

Gain a high level view of the trends shaping and driving Type 1 Diabetes market

Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.

Create an effective counter-strategy to gain a competitive advantage against those currently in the market

What's the next big thing in the global Type 1 Diabetes market landscape? Identify, understand and capitalize

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 4

1.2 List of Figures 4

2 Introduction 5

2.1 Catalyst 5

2.2 Related Reports 6

2.3 Upcoming Related Reports 6

3 Market Outlook 7

3.1 Canada 7

3.1.1 Forecast 7

3.1.2 Key Events 12

3.1.3 Drivers and Barriers 12

4 Current and Future Players 14

4.1 Overview 14

4.2 Trends in Corporate Strategy 16

4.3 Company Profiles 17

4.3.1 Novo Nordisk 17

4.3.2 Sanofi 20

4.3.3 Eli Lilly 23

5 Appendix 27

5.1 Bibliography 27

5.2 Abbreviations 43

5.3 Methodology 48

5.4 Forecasting Methodology 48

5.4.1 Diagnosed Type 1 Diabetes Patients 48

5.4.2 Percent Drug-Treated Patients 48

5.4.3 Drugs Included in Each Therapeutic Class 49

5.4.4 Launch and Patent Expiry Dates 49

5.4.5 General Pricing Assumptions 50

5.4.6 Individual Drug Assumptions 51

5.4.7 Pricing of Pipeline Agents 54

5.5 Physicians and Specialists Included in This Study 56

5.6 About the Authors 60

5.6.1 Author 60

5.6.2 Epidemiologist 60

5.6.3 Global Head of Healthcare 61

5.7 About GlobalData 62

5.8 Disclaimer 62

1.2 List of Figures

Figure 1: Sales for Type 1 Diabetes in Canada by Drug Class, 2013-2023 11

Figure 2: Company Portfolio Gap Analysis in Type 1 Diabetes, 2013-2023 16

1.1 List of Tables

Table 1: Sales Forecasts (USDm) for Type 1 Diabetes in Canada, 2013-2023 9

Table 2: Key Events Impacting Sales for T1D in Canada, 2013-2023 12

Table 3: Type 1 Diabetes Market - Drivers and Barriers in Canada, 2014 12

Table 4: Key Companies in the T1D Market in the 8MM, 2014 15

Table 5: Novo Nordisk's T1D Portfolio Assessment, 2014 19

Table 6: Novo Nordisk SWOT Analysis, 2014 20

Table 7: Sanofi's T1D Portfolio Assessment, 2014 22

Table 8: Sanofi SWOT Analysis, 2014 23

Table 9: Eli Lilly's T1D Portfolio Assessment, 2014 25

Table 10: Eli Lilly SWOT Analysis, 2014 26

Table 11: Key Launch Dates 49

Table 12: Key Patent Expiries 50

Table 13: High-Prescribing Physicians (Non-KOLs) Surveyed, by Country 59

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com

Novo Nordisk


Eli Lilly

select a license
Single User License
USD 2995 INR 220582
Site License
USD 5990 INR 441164
Corporate User License
USD 8985 INR 661745



An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@] kenresearch.com